Taiwan begins using a homegrown vaccine after months of shortages in imports
Taiwan started administering its first locally developed Covid-19 vaccine on Monday after months of struggles to get sufficient supplies of doses from major foreign vaccine makers.
President Tsai Ing-wen received a shot of the domestically made vaccine at a hospital in the capital, Taipei, giving her personal assurance of its safety.
“It didn’t hurt,” Ms. Tsai wrote in a Facebook post. “Now, I am in good spirits, and I will continue my daily work.”
The vaccine, which was developed by the Taiwan-based company Medigen, received authorization for emergency use in late July. But critics say they worry that the vaccine, which has completed Phase 2 trials, is being used before its effectiveness and safety have been proved.
Two politicians from the island’s main opposition party, Kuomintang, recently filed a complaint to a local court seeking to suspend the emergency authorization, citing the concerns over the vaccine’s safety. The court dismissed their request last week.
Taiwan, where fewer than 10 locally transmitted cases are reported each day, has favored a less heavy-handed approach to the virus than neighboring mainland China. Since an outbreak that began in May, the government has introduced a series of measures to promote vaccination and received donations of doses from countries including the United States and Japan.
In the past few months, the island’s vaccination rate has increased significantly. As of Monday, around 40 percent of residents had received at least one dose. But only about 3 percent are fully vaccinated. Taiwan has recorded 15,926 total cases of the virus and 828 deaths, according to a New York Times database.
Nearly 600,000 of Taiwan’s 23.5 million residents have registered to get Medigen shots, according to the government data.
“It didn’t hurt,” Ms. Tsai wrote in a Facebook post. “Now, I am in good spirits, and I will continue my daily work.”
The vaccine, which was developed by the Taiwan-based company Medigen, received authorization for emergency use in late July. But critics say they worry that the vaccine, which has completed Phase 2 trials, is being used before its effectiveness and safety have been proved.
Two politicians from the island’s main opposition party, Kuomintang, recently filed a complaint to a local court seeking to suspend the emergency authorization, citing the concerns over the vaccine’s safety. The court dismissed their request last week.
Taiwan, where fewer than 10 locally transmitted cases are reported each day, has favored a less heavy-handed approach to the virus than neighboring mainland China. Since an outbreak that began in May, the government has introduced a series of measures to promote vaccination and received donations of doses from countries including the United States and Japan.
In the past few months, the island’s vaccination rate has increased significantly. As of Monday, around 40 percent of residents had received at least one dose. But only about 3 percent are fully vaccinated. Taiwan has recorded 15,926 total cases of the virus and 828 deaths, according to a New York Times database.
Nearly 600,000 of Taiwan’s 23.5 million residents have registered to get Medigen shots, according to the government data.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.